Abstract
Aim:
Tumor immunotherapy aims at activating the body's own immune system to fight an existing tumor. Effective antitumor responses require tumor antigens to be presented to lymphocytes. We aimed to test the hypothesis that intratumoral administration of recombinant adenovirus encoding MIP3β would induce antitumor immunity by attracting and facilitating the interaction between lymphocytes and dendritic cells.
Methods:
A recombinant adenovirus encoding microphage inflammatory protein 3β (AdMIP3β) was constructed. The antitumor activity of AdMIP3β in BALB/c and C57BL/6 mice bearing CT26 colon adenocarcinoma and Lewis lung cancer was evaluated.
Results:
Immunotherapy with AdMIP3β resulted in significant inhibition of tumor growth and prolonged survival of tumor-bearing mice. Tumor-specific immune responses elicited by AdMIP3β include MHC class I-dependent CD8+ CTL-mediated immune response and IFN-γ response. Immunohistochemical staining demonstrated numerous CD11c+ cells and CD3+ T lymphocytes within tumor tissues of AdMIP3β-treated mice. These findings suggest that the mechanism of specific antitumor immunity induced by AdMIP3β may be involved in the chemoattraction of both T lymphocytes and DCs to the tumor site and thus facilitate the process of antigen capture and mature DC to prime naive T cells.
Conclusion:
The present study may be important in the exploration of the potential application of AdMIP3β in the treatment of a broad spectrum of tumors.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD . Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol 2002; 3: 991–8.
Igney FH, Krammer PH . Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol 2002; 71: 907–20.
Gunzer M, Janich S, Varga G, Grabbe S . Dendritc cells and tumor immunity. Semin Immunol 2001; 13: 291–302.
Pardoll DM . Therapeutic vaccination for cancer. Clin Immunol 2000; 95: 44–62.
Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811.
Schall TJ, Bacon KB . Chemokines, leukocyte trafficking and inflammation. Curr Opin Immunol 1994; 6: 865–73.
Ngo VN, Tang HL, Cyster JG . Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J Exp Med 1998; 188: 181–91.
Yanagawa Y, Onoe K . CCL19 induces rapid dendritic extension of murine dendritic cells. Blood 2002; 100: 1948–56.
Kim CH, Pelus LM, Appelbaum E, Johanson K, Anzai N, Broxmeyer HE . CCR7 ligands, SLC/6Ckine/Exodus2/TCA4 and CKβ-11/MIP-3β/ELC, are chemoattractants for CD56(+)CD16(–) NK cells and late stage lymphoid progenitors. Cell Immunol 1999; 193: 226–35.
Kim CH, Pelus LM, White JR, Broxmeyer HE . Macrophage-inflammatory protein-3β/EBI1-ligand chemokine/CKbeta-11, a CC chemokine, is a chemoattractant with a specificity for macrophage progenitors among myeloid progenitor cells. J Immunol 1998; 161: 2580–5.
Yoshida R, Imai T, Hieshima K, Kusuda J, Baba M, Kitaura M, et al. Molecular cloning of a novel human CC chemokine EBI1-ligand chemokine that is a specific functional ligand for EBI1, CCR7. J Biol Chem 1997; 272: 13803–9.
He TC, Zhou S, da Costa LT, Yu J, Kinzler KW, Vogelstein B . A simplified system for generating recombinant adenoviruses. Proc Natl Acad Sci USA 1998; 95: 2509–14.
Lu Y, Wei YQ, Tian L, Zhao X, Yang L, Hu B, et al. Immunogene therapy of tumors with vaccine based on xenogeneic epidermal growth factor receptor. J Immunol 2003; 170: 3162–70.
Li G, Tian L, Hou JM, Ding ZY, He QM, Feng P, et al. Improved therapeutic effectiveness by combining recombinant CXC chemokine ligand 10 with cisplatin in solid tumors. Clin Cancer Res 2005; 11: 4217–24.
Benichou G, Valujskikh A, Heeger PS . Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice. J Immunol 1999; 162: 352–8.
Fields RC, Shimizu K, Mule JJ . Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc Natl Acad Sci USA 1998; 95: 9482–7.
Romagnani S . The Th1/Th2 paradigm. Immunol Today 1997; 18: 263–6.
Mosmann TR, Sad S . The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17: 138–46.
Terando A, Roessler B, Mule JJ . Chemokine gene modification of human dendritic cell-based tumor vaccines using a recombinant adenoviral vector. Cancer Gene Ther 2004; 11: 165–73.
Dunussi-Joannopoulos K, Zuberek K, Runyon K, Hawley RG, Wong A, Erickson J, et al. Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses. Blood 2002; 100: 1551–8.
Vicari AP, Ait-Yahia S, Chemin K, Mueller A, Zlotnik A, Caux C . Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. J Immunol 2000; 165: 1992–2000.
Russell JH, Ley TJ . Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002; 20: 323–70.
Zhou Y, Weyman CM, Liu H, Almasan A, Zhou A . IFN-gamma induces apoptosis in HL-60 cells through decreased Bcl-2 and increased Bak expression. J Interferon Cytokine Res 2008; 28: 65–72.
Braun SE, Chen K, Foster RG, Kim CH, Hromas R, Kaplan MH, et al. The CC chemokine CKbeta-11/MIP-3beta/ELC/Exodus 3 mediates tumor rejection of murine breast cancer cells through NK cells. J Immunol 2000; 164: 4025–31.
Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, et al. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model. J Immunol 2003; 171: 6457–65.
Chada S, Ramesh R, Mhashilkar AM . Cytokine- and chemokine-based gene therapy for cancer. Curr Opin Mol Ther 2003; 5: 463–74.
Kikuchi T, Worgall S, Singh R, Moore MA, Crystal RG . Dendritic cells genetically modified to express CD40 ligand and pulsed with antigen can initiate antigen-specific humoral immunity independent of CD4+ T cells. Nat Med 2000; 6: 1154–9.
Chang AE, Redman BG, Whitfield JR, Nickoloff BJ, Braun TM, Lee PP, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res 2002; 8: 1021–32.
Rubinstein MP, Kadima AN, Salem ML, Nguyen CL, Gillanders WE, Cole DJ . Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells. J Immunol 2002; 169: 4928–35.
Boczkowski D, Nair SK, Nam JH, Lyerly HK, Gilboa E . Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. Cancer Res 2000; 60: 1028–34.
Kaplan JM, Yu Q, Piraino ST, Pennington SE, Shankara S, Woodworth LA, et al. Induction of antitumor immunity with dendritic cells transduced with adenovirus vector-encoding endogenous tumor-associated antigens. J Immunol 1999; 163: 699–707.
Acknowledgements
This work was supported by the National Basic Research Program of China (No 2004CB518800, 2004CB518807), the projects of National Natural Science Foundation of China, and the National 863 Project.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hou, Jm., Zhao, X., Tian, L. et al. Immunotherapy of tumors with recombinant adenovirus encoding macrophage inflammatory protein 3β induces tumor-specific immune response in immunocompetent tumor-bearing mice. Acta Pharmacol Sin 30, 355–363 (2009). https://doi.org/10.1038/aps.2009.4
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/aps.2009.4
